GT Biopharma (GTBP) Competitors $2.46 +0.04 (+1.45%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP vs. CVM, GRCE, LIAN, TENX, KALA, JATT, CALC, FNCH, NNVC, and OVIDShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include CEL-SCI (CVM), Grace Therapeutics (GRCE), LianBio (LIAN), Tenax Therapeutics (TENX), KALA BIO (KALA), JATT Acquisition (JATT), CalciMedica (CALC), Finch Therapeutics Group (FNCH), NanoViricides (NNVC), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. CEL-SCI Grace Therapeutics LianBio Tenax Therapeutics KALA BIO JATT Acquisition CalciMedica Finch Therapeutics Group NanoViricides Ovid Therapeutics GT Biopharma (NASDAQ:GTBP) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Which has preferable earnings and valuation, GTBP or CVM? CEL-SCI is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$7.60M-$7.00-0.35CEL-SCIN/AN/A-$26.92M-$0.48-0.57 Which has more volatility & risk, GTBP or CVM? GT Biopharma has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Does the MarketBeat Community prefer GTBP or CVM? GT Biopharma received 117 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 63.24% of users gave GT Biopharma an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformGT BiopharmaOutperform Votes11763.24% Underperform Votes6836.76% CEL-SCIOutperform VotesNo VotesUnderperform Votes25100.00% Do insiders & institutionals hold more shares of GTBP or CVM? 8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 10.9% of GT Biopharma shares are held by company insiders. Comparatively, 14.1% of CEL-SCI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate GTBP or CVM? GT Biopharma presently has a consensus price target of $11.00, suggesting a potential upside of 348.07%. Given GT Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe GT Biopharma is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to GTBP or CVM? In the previous week, GT Biopharma had 2 more articles in the media than CEL-SCI. MarketBeat recorded 2 mentions for GT Biopharma and 0 mentions for CEL-SCI. GT Biopharma's average media sentiment score of 1.45 beat CEL-SCI's score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media. Company Overall Sentiment GT Biopharma Positive CEL-SCI Neutral Is GTBP or CVM more profitable? CEL-SCI's return on equity of -238.05% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -257.47% -131.09% CEL-SCI N/A -238.05%-104.65% SummaryGT Biopharma beats CEL-SCI on 11 of the 16 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.26M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.357.3622.6118.58Price / SalesN/A241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book0.456.486.704.26Net Income-$7.60M$143.43M$3.22B$248.31M7 Day Performance7.68%1.69%1.26%1.34%1 Month Performance3.59%6.58%3.73%3.92%1 Year Performance-22.56%-2.63%15.82%5.33% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma3.5018 of 5 stars$2.46+1.4%$11.00+348.1%-19.3%$6.26MN/A-0.358Short Interest ↓Positive NewsGap DownCVMCEL-SCIN/A$0.26+2.5%N/A-80.1%$21.97MN/A-0.5443Analyst ForecastGRCEGrace Therapeutics2.3935 of 5 stars$2.15+2.9%$12.00+458.1%N/A$21.80MN/A-1.85N/APositive NewsGap DownLIANLianBioN/A$0.20flatN/A-41.5%$21.61MN/A-0.25110News CoverageGap DownTENXTenax Therapeutics2.5552 of 5 stars$5.14-3.4%$18.00+250.2%+47.7%$21.32MN/A-0.979Analyst ForecastKALAKALA BIO3.4989 of 5 stars$3.29-4.6%$15.00+355.9%-42.5%$21.23M$3.89M-0.2630Positive NewsGap DownJATTJATT AcquisitionN/A$1.23+7.0%N/A-67.4%$21.22MN/A0.003High Trading VolumeCALCCalciMedica2.2936 of 5 stars$1.55-0.2%$18.00+1,063.5%-72.6%$20.86MN/A-1.4330News CoverageFNCHFinch Therapeutics GroupN/A$12.95-0.4%N/A+434.2%$20.80M$110,000.00-1.47190Gap DownNNVCNanoViricidesN/A$1.30-2.3%N/A+14.2%$20.33MN/A-1.8120Gap DownOVIDOvid Therapeutics4.455 of 5 stars$0.29-1.1%$3.03+962.8%-89.3%$20.29M$566,000.00-0.6160Gap Up Related Companies and Tools Related Companies CEL-SCI Alternatives Grace Therapeutics Alternatives LianBio Alternatives Tenax Therapeutics Alternatives KALA BIO Alternatives JATT Acquisition Alternatives CalciMedica Alternatives Finch Therapeutics Group Alternatives NanoViricides Alternatives Ovid Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTBP) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GTBP Stock Free GTBP Stock Alerts